scispace - formally typeset
G

George N. Abraham

Researcher at University of Rochester

Publications -  32
Citations -  3385

George N. Abraham is an academic researcher from University of Rochester. The author has contributed to research in topics: Antibody & Immunoglobulin G. The author has an hindex of 21, co-authored 32 publications receiving 3353 citations.

Papers
More filters
Journal Article

The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

TL;DR: It is demonstrated that genetic modification of tumor cells may be useful for developing cancer therapies and the mechanism of this "bystander effect" was related to the process of apoptotic cell death when HSV-TK-positive cells were exposed to GCV.
Journal Article

Human monocytes and U937 cells bear two distinct Fc receptors for IgG.

TL;DR: The simplest interpretation of these results is that human monocytes and U937 cells bear two classes of IgG FcR, one of 72 Kd and the other, as described above, of 40 Kd.
Journal ArticleDOI

Role of cytomegalovirus in the T cell changes seen in elderly individuals.

TL;DR: It is indicated that prior infection with CMV, as reflected by CMV serological status, has important effects on T cell subsets and surface markers and must be considered whenever evaluating age-related changes in immunological parameters.
Journal ArticleDOI

Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes.

TL;DR: Although anti- p40 did not directly aggregate platelets in the concentrations employed, cross-linking with F(ab')2 goat anti-murine Ig induced apyrase-sensitive aggregation of anti-p40-treated platelets indicates that p40 possesses transmembrane linkage for platelet activation and secretion.
Journal ArticleDOI

A technique for the removal of pyroglutamic acid from the amino terminus of proteins using calf liver pyroglutamate amino peptidase

TL;DR: An improved technique has been developed which can quickly and easily unblock proteins and peptides containing pyrrolidone carboxylic acid (PCA) or pyroglutamic acid in the amino terminal position utilizing commercially available pyrog lutamate amino peptidase isolated from calf liver.